Do quantitative levels of antispike-IgG antibodies aid in predicting protection from SARS-CoV-2 infection? Results from a longitudinal study in a police cohort.
COVID-19
SARS-CoV-2
antispike-IgG
quantitaive antispike-IgG
serology
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
04
06
2023
received:
25
03
2023
accepted:
11
06
2023
medline:
3
7
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
In a COVID-19 sero-surveillance cohort study with predominantly healthy and vaccinated individuals, the objectives were (i) to investigate longitudinally the factors associated with the quantitative dynamics of antispike (anti-S1) IgG antibody levels, (ii) to evaluate whether the levels were associated with protection from SARS-CoV-2 infection, and (iii) to assess whether the association was different in the pre-Omicron compared with the Omicron period. The QuantiVac Euroimmun ELISA test was used to quantify anti-S1 IgG levels. The entire study period (16 months), the 11-month pre-Omicron period and the cross-sectional analysis before the Omicron surge included 3219, 2310, and 895 reactive serum samples from 949, 919, and 895 individuals, respectively. Mixed-effect linear, mixed-effect time-to-event, and logistic regression models were used to achieve the objectives. Age and time since infection or vaccination were the only factors associated with a decline of anti-S1 IgG levels. Higher antibody levels were significantly associated with protection from SARS-CoV-2 infection (0.89, 95% confidence interval [CI] 0.82-0.97), and the association was higher during the time period when Omicron was predominantly circulating compared with the ones when Alpha and Delta variants were predominant (adjusted hazard ratio for interaction 0.66, 95% CI 0.53-0.84). In a prediction model, it was estimated that >8000 BAU/mL anti-S1 IgG was required to reduce the risk of infection with Omicron variants by approximately 20%-30% for 90 days. Though, such high levels were only found in 1.9% of the samples before the Omicron surge, and they were not durable for 3 months. Anti-S1 IgG antibody levels are statistically associated with protection from SARS-CoV-2 infection. However, the prediction impact of the antibody level findings on infection protection is limited.
Substances chimiques
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28904Informations de copyright
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Références
National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. 2020;20(12):1390-1400.
Riester E, Findeisen P, Hegel JK, et al. Performance evaluation of the Roche Elecsys anti-SARS-CoV-2 S immunoassay. J Virol Methods. 2021;297:114271.
Riester E, Majchrzak M, Mühlbacher A, et al. Multicentre performance evaluation of the elecsys anti-SARS-CoV-2 immunoassay as an aid in determining previous exposure to SARS-CoV-2. Infect Dis Ther. 2021;10(4):2381-2397.
Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704.
Rubio-Acero R, Castelletti N, Fingerle V, et al. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in pre-characterized oligo-/asymptomatic patients. Infect Dis Ther. 2021;10(3):1505-1518.
Sendi P, Baldan R, Thierstein M, et al. A multidimensional cross-sectional analysis of coronavirus disease 2019 seroprevalence among a police officer cohort: the PoliCOV-19 study. Open Forum Infect Dis. 2021;8(12):ofab524.
Sendi P, Branca M, Büchi AE, Widmer N, Tande AJ, Gowland P. The disease burden of Delta and Omicron variants of severe acute respiratory syndrome coronavirus 2 in a predominantly vaccinated and healthy cohort. Clin Microbiol Infect. 2022;28(12):1659-1661.
Sendi P, Thierstein M, Widmer N, et al. Serosurveillance after a COVID-19 vaccine campaign in a Swiss police cohort. Immun Inflamm Dis. 2022;10(7):e640.
Dolscheid-Pommerich R, Bartok E, Renn M, et al. Correlation between a quantitative anti-SARS-CoV-2 IgG ELISA and neutralization activity. J Med Virol. 2022;94(1):388-392.
Federal Office of Public Health. 2022. COVID-19 Switzerland-Epidemiological course, Switzerland and Lichtenstein, Virus variants. Accessed June 22, 2022. https://www.covid19.admin.ch/en/epidemiologic/virus-variants?variantZoomHospSeg=2022-04-10_2022-07-10&variantZoomMonitoringSeg=2021-11-07_2022-02-06
Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022;3(4):e274-e283.
Nanishi E, Levy O, Ozonoff A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum Vaccines Immunother. 2022;18(5):2045857.
Eyre DW, Taylor D, Purver M, et al. Effect of Covid-19 vaccination on transmission of Alpha and Delta variants. N Engl J Med. 2022;386(8):744-756.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211.
Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86-88.
Liu KT, Han YJ, Wu GH, Huang KYA, Huang PN. Overview of neutralization assays and international standard for detecting SARS-CoV-2 neutralizing antibody. Viruses. 2022;14(7):1560.
Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C. How to interpret and use COVID-19 serology and immunology tests. Clin Microbiol Infect. 2021;27(7):981-986.
Montesinos I, Dahma H, Wolff F, et al. Neutralizing antibody responses following natural SARS-CoV-2 infection: dynamics and correlation with commercial serologic tests. J Clin Virol. 2021;144:104988.
Müller L, Kannenberg J, Biemann R, Hönemann M, Ackermann G, Jassoy C. Comparison of the measured values of quantitative SARS-CoV-2 spike antibody assays. J Clin Virol. 2022;155:105269.
Baumgarth N, Nikolich-Žugich J, Lee FEH, Bhattacharya D. Antibody responses to SARS-CoV-2: let's stick to known knowns. J Immunol. 2020;205(9):2342-2350.
Girl P, Mantel S, von Buttlar H, Wölfel R, Müller K. Side-by-side evaluation of three commercial ELISAs for the quantification of SARS-CoV-2 IgG antibodies. Viruses. 2022;14(3):577.
Cocomazzi G, Piazzolla V, Squillante MM, et al. Early serological response to BNT162b2 mRNA vaccine in healthcare workers. Vaccines. 2021;9(8):913.
Schumacher F, Mrdenovic N, Scheicht D, Pons-Kühnemann J, Scheibelhut C, Strunk J. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with rituximab: a case-control study (COVID-19VacRTX). Rheumatology. 2022;61(10):3912-3918.
Stępień M, Zalewska M, Knysz B, et al. How humoral response and side effects depend on the type of vaccine and past SARS-CoV-2 infection. Vaccines. 2022;10(7):1042.
Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377-1380.